Intermountain Healthcare: Pursuing Precision Medicine Custom Case Solution & Analysis

Evidence Brief: Intermountain Healthcare Precision Medicine

Financial Metrics

• Annual operating revenue: 6.7 billion dollars.
• Precision medicine pilot results: Targeted therapies cost 700 dollars less per week than standard chemotherapy for late-stage cancer patients.
• Survival outcomes: Progression-free survival doubled from 8.9 weeks to 17.8 weeks for patients receiving genomics-informed care.
• Investment: Initial funding for the Precision Genomics program was 10 million dollars.
• Cost of sequencing: Dropped from 100 million dollars in 2001 to approximately 1,000 dollars by the time of the case.

Operational Facts

• Network size: 22 hospitals and 185 clinics.
• Staffing: 1,400 employed physicians and 2,500 affiliated physicians.
• Geographic footprint: Primary operations in Utah and southeastern Idaho.
• Data infrastructure: Transitioning to Cerner for a unified electronic health record system.
• Research capacity: Access to a biobank containing over 5 million tissue samples.

Stakeholder Positions

• Marc Harrison, CEO: Views precision medicine as a fundamental shift from volume to value-based care.
• Lincoln Nadauld, Director of Precision Genomics: Advocate for scaling genomics beyond oncology to primary care and preventative medicine.
• SelectHealth: Intermountain healthcare health plan; seeks evidence of long-term cost reduction before expanding coverage.
• External Payers: Resistant to reimbursing high-cost genomic testing without standardized clinical utility data.
• Physicians: Varied levels of buy-in; concern regarding the complexity of interpreting genomic reports.

Information Gaps

• Long-term survival data: The pilot focused on late-stage cancer; data for early-stage or preventative genomics is absent.
• Internal rate of return: Specific financial projections for a full-scale rollout across all clinical areas are not detailed.
• Competitor benchmarks: Limited data on the cost-efficiency of precision medicine programs at peer institutions like Mayo Clinic or Geisinger.

Strategic Analysis: Scaling the Precision Model

Core Strategic Question

• How can Intermountain Healthcare transition precision medicine from a specialized oncology pilot into a standardized, commercially viable service line across its entire integrated network?
• How should the organization balance the high upfront costs of sequencing with the long-term savings of value-based care?

Structural Analysis

Applying the Value Chain framework reveals that Intermountain Healthcare possesses a unique advantage in the integration of its biobank and clinical data. The primary bottleneck is not the technology of sequencing, but the clinical decision support required to make that data actionable for non-specialist physicians. Using the Jobs-to-be-Done lens, patients are not looking for genomic tests; they are looking for the most effective treatment with the fewest side effects on the first attempt. Intermountain Healthcare is currently the only provider in its region capable of closing this loop internally.

Strategic Options

• Option 1: Full Internal Integration. Embed genomic testing into standard protocols for all oncology, cardiovascular, and rare disease patients.
  • Rationale: Maximizes the benefits of the integrated delivery network and SelectHealth alignment.
  • Trade-offs: High immediate capital expenditure and potential for physician burnout.
  • Resources: Significant IT upgrades and clinical educator hiring.
• Option 2: Commercial Spin-off. Create a separate entity to sell genomic interpretation services to external hospital systems.
  • Rationale: Generates external revenue to subsidize internal patient costs.
  • Trade-offs: Diverts leadership attention and risks intellectual property leakage.
  • Resources: Separate sales force and commercial-grade software interface.
• Option 3: Selective Partnership. Partner with a third-party sequencing giant to handle the lab work while Intermountain Healthcare retains the data and interpretation.
  • Rationale: Reduces capital risk and allows focus on clinical application.
  • Trade-offs: Loss of margin on the testing phase and reliance on external timelines.
  • Resources: Legal and procurement expertise for contract management.

Preliminary Recommendation

Intermountain Healthcare should pursue Option 1. The organization is uniquely positioned as an integrated system to capture the downstream savings that precision medicine generates. By keeping the program internal, the hospital system can prove the value-based model to SelectHealth, creating a blueprint for other payers. This path strengthens the core mission and utilizes the existing biobank assets most effectively.

Implementation Roadmap: Precision Integration

Critical Path

• Month 1-3: Integrate genomic data fields into the Cerner electronic health record to ensure results are visible to all treating physicians.
• Month 3-6: Formalize a shared-savings agreement with SelectHealth to reimburse genomic sequencing for a broader range of indications.
• Month 6-12: Launch a system-wide physician education program focused on interpreting genomic reports and selecting targeted therapies.
• Month 12+: Expand sequencing to cardiovascular and pediatric rare disease departments.

Key Constraints

• Data Interpretation: The shortage of genetic counselors and molecular pathologists will limit the speed at which reports can be processed.
• Payer Reimbursement: External payers will remain a barrier until Intermountain Healthcare can produce 24 months of cost-savings data from its own internal population.

Risk-Adjusted Implementation Strategy

The implementation will follow a phased rollout to mitigate operational friction. Rather than a system-wide mandate, Intermountain Healthcare will start with the 1,400 employed physicians who are already within the organizational culture. Contingency plans include hiring contract genetic counselors if internal capacity is exceeded during the first six months. Success will be measured not by the number of tests performed, but by the reduction in total cost of care for the sequenced patient population.

Executive Review and BLUF

BLUF

Intermountain Healthcare must aggressively integrate precision medicine into its standard clinical workflow. The pilot data is definitive: doubling progression-free survival while reducing weekly costs by 700 dollars is a rare alignment of clinical excellence and fiscal responsibility. Delaying full integration invites competitors to commoditize sequencing, stripping Intermountain Healthcare of its first-mover advantage in data-driven care. The organization should prioritize internal scaling over commercial spin-offs to solidify its position as the leader in value-based medicine. Success requires immediate Cerner integration and a locked-in reimbursement model with SelectHealth. APPROVED FOR LEADERSHIP REVIEW.

Dangerous Assumption

The analysis assumes that the cost savings seen in late-stage oncology will translate proportionally to other clinical areas like cardiology or primary care. This is unproven and represents a significant financial risk if the upfront cost of sequencing does not yield immediate downstream savings in those departments.

Unaddressed Risks

• Data Security: A breach of the genomic database would result in irreparable reputational damage and legal liability, potentially exceeding the financial gains of the program. High probability, extreme consequence.
• Regulatory Shift: Changes in FDA oversight of laboratory-developed tests could increase the cost and complexity of internal sequencing overnight. Moderate probability, high consequence.

Unconsidered Alternative

The team did not fully explore a Patient-Pay model for elective genomics. Offering elective sequencing for healthy patients interested in pharmacogenomics or disease predisposition could provide an immediate cash flow stream without waiting for payer negotiations. This would utilize existing lab capacity and build a larger data set for future research.

MECE Analysis of Strategic Pillars